Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2002 1
2003 1
2006 1
2008 1
2014 1
2017 1
2018 2
2023 1
2024 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Treatment intensification following glucagon-like peptide-1 receptor agonist in type 2 diabetes: Comparative effectiveness analyses between free vs. fixed combination of GLP-1 RA and basal insulin. RESTORE-G real-world study.
Candido R, Nicolucci A, Larosa M, Rossi MC, Napoli R; RESTORE-G (Retrospective analysis on the therapeutic approaches after GLP-1 RA treatment in type 2 diabetes patients) Study Group. Candido R, et al. Nutr Metab Cardiovasc Dis. 2024 Aug;34(8):1846-1853. doi: 10.1016/j.numecd.2024.03.023. Epub 2024 Mar 23. Nutr Metab Cardiovasc Dis. 2024. PMID: 38693036 Free article.
Treatment intensification following glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes: The RESTORE-G real-world study.
Candido R, Nicolucci A, Larosa M, Rossi MC, Napoli R; RESTORE-G (Retrospective analysis on the therapeutic approaches after GLP-1 RA treatment in type 2 diabetes patients) Study Group. Candido R, et al. Nutr Metab Cardiovasc Dis. 2023 Nov;33(11):2294-2305. doi: 10.1016/j.numecd.2023.07.025. Epub 2023 Jul 22. Nutr Metab Cardiovasc Dis. 2023. PMID: 37679243 Free article.
Treatment intensification following glucagon-like peptide-1 receptor agonists in type 2 diabetes: Comparative effectiveness analyses between different basal insulins. RESTORE-G real-world study.
Napoli R, Nicolucci A, Larosa M, Rossi MC, Candido R; RESTORE‐G (Retrospective analysis on the therapeutic approaches after GLP‐1 RA treatment in type 2 diabetes patients) Study Group. Napoli R, et al. Diabetes Obes Metab. 2024 Sep;26(9):3576-3586. doi: 10.1111/dom.15697. Epub 2024 Jun 10. Diabetes Obes Metab. 2024. PMID: 38853712
Metabolic control and complications in Italian people with diabetes treated with continuous subcutaneous insulin infusion.
Lepore G, Bonfanti R, Bozzetto L, Di Blasi V, Girelli A, Grassi G, Iafusco D, Laviola L, Rabbone I, Schiaffini R, Bruttomesso D; Italian Study Group on the Diffusion of CSII. Lepore G, et al. Nutr Metab Cardiovasc Dis. 2018 Apr;28(4):335-342. doi: 10.1016/j.numecd.2017.12.001. Epub 2017 Dec 9. Nutr Metab Cardiovasc Dis. 2018. PMID: 29428572
In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine.
Bruttomesso D, Crazzolara D, Maran A, Costa S, Dal Pos M, Girelli A, Lepore G, Aragona M, Iori E, Valentini U, Del Prato S, Tiengo A, Buhr A, Trevisan R, Baritussio A. Bruttomesso D, et al. Among authors: crazzolara d. Diabet Med. 2008 Mar;25(3):326-32. doi: 10.1111/j.1464-5491.2007.02365.x. Diabet Med. 2008. PMID: 18307459 Clinical Trial.
The use of degrees of certainty to evaluate knowledge.
Bruttomesso D, Gagnayre R, Leclercq D, Crazzolara D, Busata E, d'Ivernois JF, Casiglia E, Tiengo A, Baritussio A. Bruttomesso D, et al. Among authors: crazzolara d. Patient Educ Couns. 2003 Sep;51(1):29-37. doi: 10.1016/s0738-3991(02)00226-4. Patient Educ Couns. 2003. PMID: 12915277 Free article.
12 results